Orris

Help me justify the use of endoscopic approach for breast lumpectomy with evidence. What are its benefits

Reading File
Endoscopic breast lumpectomy is a minimally invasive alternative to open surgery that uses small incisions and a camera. Key benefits include better cosmesis (hidden scars), reduced wound morbidity, and potentially equivalent oncologic outcomes. Let me search the textbook library and recent literature simultaneously for a thorough evidence-based answer.
Searching sources...
Finding Sources
Searching PubMed

endoscopic breast lumpectomy minimally invasive

Searching the Web

endoscopic approach breast lumpectomy benefits evidence cosmesis oncologic outcomes

Good - I found several relevant PubMed papers and web sources. Let me now fetch the key articles in parallel for detailed evidence.
Reading Article

PMID: 39013811

Reading Article

PMID: 36203177

Reading Article

PMID: 41814250

Reading Article

PMID: 42126517

Reading Web Page

https://ales.amegroups.org/article/view/10607/html

I now have comprehensive evidence. Let me also get the multicenter Korean robotic/endoscopic BCS study and search for the systematic review data on margin rates.
Reading Article

PMID: 40789780

Searching PubMed

endoscopic breast conserving surgery oncologic safety margin recurrence

I now have enough comprehensive evidence to construct a thorough, well-cited answer. Here is the full evidence-based justification:

Endoscopic Approach for Breast Lumpectomy (Breast-Conserving Surgery): Evidence-Based Justification

Background

Endoscopic breast-conserving surgery (E-BCS) uses CO2 insufflation, a concealed incision (typically axillary or periareolar), a camera port, and ultrasonic dissection to excise breast tumors without a visible scar on the breast mound itself. It has been practiced for over two decades in East Asia and is now gaining traction globally.

1. Cosmetic Outcomes - The Primary Advantage

This is the strongest and most consistently proven benefit across all levels of evidence.
What the evidence shows:
  • In a single-institution study of 100 consecutive E-BCS patients, 98% of patients were satisfied with scar appearance, with the small incisions placed in inconspicuous areas (axilla or periareolar). The margin involvement rate was only 4%, consistent with open BCS literature (0-20%), per Farmah et al. (2025) in ALES.
  • A comparative study by Xie et al. (2022) in World J Surg Oncol (PMID: 36203177) compared single-port insufflation E-BCS (SIE-BCS, n=63) vs. conventional open BCS (C-BCS, n=117) in stage I-II breast cancer:
    • Mean incision length: 3.4 cm (SIE-BCS) vs. 8.6 cm (C-BCS) (p<0.001)
    • BREAST-Q scores for physical well-being (chest) and psychological well-being were significantly better in the SIE-BCS group
    • No significant difference in breast or sexual well-being scores (both approaches preserved breast tissue adequately)
  • A 2025 meta-analysis comparing endoscopic vs. conventional nipple-sparing mastectomy (PMC12090896) confirmed: OR 1.88 (95% CI 1.09-3.26, p=0.02) for satisfactory cosmetic results favoring endoscopic approach, with low heterogeneity (I² = 0%).
  • A 2026 Indian feasibility series (Mathan et al., BMC Surg, PMID: 41814250) reported cosmetic satisfaction score of 4.6/5 (Likert scale), with preserved breast contour and no visible deformity in all patients.

2. Oncologic Safety - Non-Inferior to Open BCS

A major concern is whether endoscopic access compromises margin clearance or recurrence risk. The evidence is reassuring:
  • Margin positivity rates of 4% in E-BCS are within published open BCS benchmarks (0-20%) - Farmah et al. 2025.
  • Xie et al. (2022) showed that SIE-BCS did not increase risk of local recurrence or metastasis vs. conventional BCS on preliminary logistic regression analysis.
  • A 2024 systematic review (Wang et al., PMID: 39013811) concluded that endoscopic BCS "improved patients' postoperative psychological health and quality of life, particularly in scar-free surgery" while acknowledging ongoing debate from limited intraoperative visibility in some settings.
  • In the first multicenter robot-assisted BCS study (KoREa-BSG, Choi et al. 2025, PMID: 40789780) with 150 patients across 7 institutions:
    • Only 1 patient (0.7%) required reoperation for positive permanent margin
    • Recurrence rate: 1.3% at median follow-up
    • No conversions to open surgery, no mortality
    • Complication rate: 4% (predominantly minor skin burns from energy devices)
  • A 2026 comparative study (Huang et al., PMID: 42126517, n=132) found that in both robotic-BCS and E-BCS groups, only 1 patient each had a positive margin, both converted to negative after re-excision, confirming oncologic adequacy.

3. Reduced Adverse Effects of Radiation

  • Xie et al. (2022) showed SIE-BCS was associated with decreased rates of adverse effects from post-operative radiotherapy, likely because the smaller incision and less tissue disruption result in a better-defined, less scarred radiation field.

4. Psychological and Quality of Life Benefits

  • Significantly better psychological well-being scores on BREAST-Q in E-BCS vs. C-BCS [Xie et al. 2022]
  • The 2025 ALES review (Farmah et al.) confirmed "improved psychosocial outcomes and satisfaction for the patients" vs. open techniques.
  • The 2024 systematic review (Wang et al.) specifically highlighted benefit in "postoperative psychological health and quality of life, particularly in scar-free surgery."

5. Perioperative Advantages

ParameterE-BCSOpen BCS
Incision length3.4 cm8.6 cm
Visible breast scarNone (axillary)Present
Blood lossLow (avg 60 ml)Comparable
Drain useOften not requiredOften required
Post-op painLower (immediate)Higher
Hospital stayShort (median 5.4 days in robotic series)Similar
  • Pain: VAS scores were significantly lower immediately post-op in endoscopic vs. conventional approaches (meta-analysis, PMC12090896), though the difference attenuated after a few days.
  • Drain: In the SAGES single-site series, drains were not required in most cases.

6. Sentinel Lymph Node Biopsy (SLNB) Can Be Done Simultaneously

A practical concern is whether axillary staging is still feasible. The 2026 Indian series (Mathan et al., PMID: 41814250) demonstrated that SLNB can be performed entirely through the same single axillary incision as E-BCS, without compromising sentinel node retrieval. All three patients had negative margins and successful node mapping.

7. Limitations and Caveats to Address in Justification

To be credible, any justification should acknowledge:
  • Longer operative time: SIE-BCS averages ~55-195 min vs. ~140 min for open BCS. This is a real trade-off.
  • Learning curve: Requires advanced laparoscopic skills; not immediately available in all centers.
  • Patient selection: Best suited for tumors ≤3 cm, non-ptotic breasts, and patients who are not excessively large-breasted.
  • Cost: Requires specialized equipment (CO2 insufflator, 5mm ports, ultrasonic dissectors, possibly robotic platform).
  • Long-term oncologic data: Still maturing; most studies have follow-up of 1-3 years. Multicenter prospective RCTs are lacking.

Summary of Evidence Strength

DomainEvidenceQuality
Cosmesis / patient satisfactionConsistently superior (98% satisfaction; OR 1.88 for cosmetic satisfaction)Moderate (comparative cohorts + meta-analysis)
Oncologic safety (margin rate)Non-inferior (4% positive margins, within open BCS range)Moderate
Local recurrenceComparable (1.3% in multicenter series)Low-moderate (limited follow-up)
Psychological/QoLSignificantly improved (BREAST-Q)Moderate
Radiotherapy toleranceImprovedLow (single study)
SLNB feasibilityDemonstratedLow (case series)
Key citations for your justification:
  1. Xie et al. 2022 - World J Surg Oncol - comparative cohort, n=180, BREAST-Q outcomes
  2. Wang et al. 2024 - Systematic Review (PMID 39013811) - systematic review of endoscopic BCS development
  3. Mathan et al. 2026 - BMC Surg (PMID 41814250) - feasibility with simultaneous SLNB
  4. Choi et al. 2025 - Surg Endosc (PMID 40789780) - first multicenter robot-assisted BCS study (7 centers, n=150)
  5. Huang et al. 2026 - J Robot Surg (PMID 42126517) - robotic vs endoscopic BCS, n=132
  6. Carroll et al. 2025 meta-analysis - PMC12090896 - OR 1.88 for cosmetic satisfaction
  7. Farmah et al. 2025 - ALES narrative review - comprehensive minimally invasive breast surgery review
This is a shared conversation. Sign in to Orris to start your own chat.